Artificial pancreas: An emerging approach to treat Type 1 diabetes

Expert Review of Medical Devices

Volumn 6, Issue 4, 2009, Pages 401-410

  Kumareswaran, Kavita ^a   Evans, Mark L ^a   Hovorka, Roman ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Closed loop insulin delivery; Continuous glucose monitor; Control algorithm; Diabetes; Euglycemia; Insulin pump; Subcutaneous route

Indexed keywords

HEMOGLOBIN A1C; INSULIN; PRAMLINTIDE;

ACCURACY; ARTIFICIAL PANCREAS; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DEVICE; DRUG DELIVERY SYSTEM; FEASIBILITY STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; GLYCEMIC CONTROL; HEALTH CARE COST; HORMONAL REGULATION; HUMAN; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN RELEASE; LIFESPAN; PANCREAS ISLET TRANSPLANTATION; PATIENT MONITORING; RELIABILITY; REVIEW; SAFETY;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DIAGNOSIS, COMPUTER-ASSISTED; DRUG THERAPY, COMPUTER-ASSISTED; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; HUMANS; INSULIN INFUSION SYSTEMS; PANCREAS, ARTIFICIAL; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 69949178701     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.09.23     Document Type: Review

References (78)

1. Guyton A, Hall J. Textbook of Medical Physiology. Elsevier Saunders, PA, USA (2006).
2. Karvonen M, Viik-Kajander M, Moltchanova E et al. Incidence of childhood Type 1 diabetes worldwide. Diabetes Care 23(10), 1516-1526 (2000).
3. Bessaoud K, Boudraa G, de Ropolo MM et al. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet. Med. 23(8), 857-866 (2006).
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med, 329(14), 977-986 (1993).
5. Pickup JC. Are insulin pumps underutilized in Type 1 diabetes? Yes. Diabetes Care 29(6), 1449-1452 (2006).
6. Pickup JC, Kidd J, Burmiston S, Yemane N. Determinants of glycaemic control in Type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab. Res. Rev. 22(3), 232-237 (2006).
7. Bruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabetes Metab. Res. Rev. 25(2), 99-111 (2009).
8. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with Type 1 diabetes: meta-analysis of randomised controlled trials. Br. Med. J. 324(7339), 705-708 (2002).
9. Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and Type 2 diabetes. Diabetes Care 31(Suppl. 2), S140-S145 (2008).
10. Pickup JC, Hammond P. NICE guidance on continuous subcutaneous insulin infusion 2008: review of the technology appraisal guidance. Diabet. Med. 26(1), 1-4 (2009).
11. Selam JL. External and implantable insulin pumps: current place in the treatment of diabetes. Exp. Clin. Endocrinol. Diabetes 109, S333-S340 (2001).
12. Renard E. Implantable closed-loop glucose-sensing and insulin delivery: the future for insulin pump therapy. Curr. Opin. Pharmacol. 2(6), 708-716 (2002).
13. Renard E, Schaepelynck-Bélicar P; the EVADIAC Group. Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab. 33(2), 158-166 (2007).
14. Gin H, Renard E, Melki V et al. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in Type 1 diabetic patients: the EVADIAC experience. Diabetes Metab. 29(6), 602-607 (2003).
15. Renard E, Costalat G, Chevassus H, Bringer J. Closed loop insulin delivery using implanted insulin pumps and sensors in Type 1 diabetic patients. Diabetes Res. Clin. Pract. 74, S173-S177 (2006).
16. Shapiro AMJ, Lakey JRT, Ryan EA et al. Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343(4), 230-238 (2000).
17. Ryan EA, Paty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes 54(7), 2060-2069 (2005).
18. Jones PM, Courtney ML, Burns CJ, Persaud SJ. Cell-based treatments for diabetes. Drug Discov. Today 13(19-20), 888-893 (2008).
19. Wojcicki JM, Ladyzynski P. Toward the improvement of diabetes treatment: recent developments in technical support. J. Artif. Organs 6(2), 73-87 (2003).
20. Farmer TG, Edgar TF, Peppas NA. The future of open- and closed-loop insulin delivery systems. J. Pharm. Pharmacol. 60(1), 1-13 (2008).
21. Kadish AH. Automation control of blood sugar. I. Servomechanism for glucose monitoring and control. Am. J. Med. Electron. 3(2), 82-86 (1964).
22. Clemens AH, Chang PH, Myers RW. The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS). Horm. Metab. Res. Suppl. 7, 23-33 (1977).
23. Clarke WL, Cox D, Gonderfrederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of systems for self-monitoring of blood-glucose. Diabetes Care 10(5), 622-628 (1987).
24. Kovatchev B, Anderson S, Heinemann L, Clarke W. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care 31(6), 1160-1164 (2008).
25. Kovatchev BP, Gonder-Frederick LA, Cox DJ, Clarke WL. Evaluating the accuracy of continuous glucose-monitoring sensors. Diabetes Care 27(8), 1922-1928 (2004).
26. Mastrototaro J. The MiniMed Continuous Glucose Monitoring System (CGMS). J. Pediatr. Endocrinol. Metab. 12, 751-758 (1999).
27. Rebrin K, Steil GM, Van Antwerp WP, Mastrototaro JJ. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am. J. Physiol. Endocrinol. Metab. 277(3), E561-E571 (1999).
28. Sachedina N, Pickup JC. Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects. Diabet. Med. 20(12), 1012-1015 (2003).
29. Garg S, Jovanovic L. Relationship of fasting and hourly glucose levels to HbA(1c) values blood. Diabetes Care 29(12), 2644-2649 (2006).
30. Mastrototaro J, Soundararajan G, Cooper K, Shah R. Accuracy of real-time continuous glucose monitoring in the MiniMed paradigm system. Diabetes 56, A112 (2007).
31. Wilson DM, Beck RW, Tamborlane WV et al. The accuracy of the FreeStyle Navigator continuous glucose monitoring system in children with Type 1 diabetes. Diabetes Care 30(1), 59-64 (2007).
32. Hirsch IB, Armstrong D, Bergenstal RM et al. Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM). Diabetes Technol. Ther. 10(4), 232-244 (2008).
33. Tamborlane WV, Beck RW, Bode BW et al.; the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of Type 1 diabetes. N. Engl. J. Med. 359(14), 1464-1476 (2008).
34. Hirsch IB, Abelseth J, Bode BW et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol. Ther. 10(5), 377-383 (2008).
35. Hovorka R. The future of continuous glucose monitoring: closed loop. Curr. Diabetes Rev. 4(3), 269-279 (2008).
36. Buckingham B, Block J, Burdick J et al. Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol. Ther. 7(3), 440-447 (2005).
37. Bequette BW. A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. Diabetes Technol. Ther. 7(1), 28-47 (2005).
38. Steil GM, Panteleon AE, Rebrin K. Closed-loop insulin delivery - the path to physiological glucose control. Adv. Drug Deliv. Rev. 56(2), 125-144 (2004).
39. Hovorka R, Canonico V, Chassin LJ et al. Nonlinear model predictive control of glucose concentration in subjects with Type 1 diabetes. Physiol. Meas. 25(4), 905-920 (2004).
40. Schaller HC, Schaupp L, Bodenlenz M et al. On-line adaptive algorithm with glucose prediction capacity for subcutaneous closed loop control of glucose: evaluation under fasting conditions in patients with Type 1 diabetes. Diabet. Med. 23(1), 90-93 (2006).
41. Dassau E, Bequette BW, Buckingham BA, Doyle FJ. Detection of a meal using continuous glucose monitoring: implications for an artificial β-cell. Diabetes Care 31(2), 295-300 (2008).
42. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet. Med. 23(1), 1-12 (2006).
43. Plank J, Wutte A, Brunner G et al. A direct comparison of insulin aspart and insulin lispro in patients with Type 1 diabetes. Diabetes Care 25(11), 2053-2057 (2002).
44. Hovorka R, Shojaee-Moradie F, Carroll PV et al. Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT. Am. J. Physiol. Endocrinol. Metab. 282(5), E992-E1007 (2002).
45. Albisser AM, Leibel BS, Ewart TG, Davidova Z, Botz CK, Zingg W. Artificial endocrine pancreas. Diabetes 23(5), 389-396 (1974).
46. Pfeiffer EF, Thum C, Clemens AH. Artificial β cell - continuous control of blood-sugar by external regulation of insulin infusion. Horm. Metab. Res. 6(5), 339-342 (1974).
47. Pfeiffer EF. The glucose sensor: the missing link in diabetes therapy. Horm. Metab. Res. Suppl. 24, 154-164 (1990).
48. Selam JL, Charles MA. Devices for insulin administration. Diabetes Care 13(9), 955-979 (1990).
49. Goriya Y, Kawamori R, Shichiri M, Abe H. Development of an aritficial β-cell system and its validation in depancreatized dogs - physiological restoration of blood-glucose homestasis. Med. Prog. Technol. 6(3), 99-108 (1979).
50. Shichiri M, Kawamori R, Yamasaki Y, Hakui N, Abe H. Wearable artificial endocrine pancreas with needle-type glucose sensor. Lancet 2(8308), 1129-1131 (1982).
51. Shimoda S, Nishida K, Sakakida M et al. Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas. Front. Med. Biol. Eng. 8(3), 197-211 (1997).
52. Shimoda S, Nishida K, Sakakida M, Matsuo Y, Araki E. Development of closed-loop intraperitoneal insulin infusion algorithm for a implantable artificial endocrine pancreas. Diabetes 50, A3 (2001).
53. Steil GM, Rebrin K, Janowski R, Darwin C, Saad MF. Modeling β-cell insulin secretion - implications for closed-loop glucose homeostasis. Diabetes Technol. Ther. 5(6), 953-964 (2003).
54. Panteleon AE, Loutseiko M, Steil GM, Rebrin K. Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. Diabetes 55(7), 1995-2000 (2006).
55. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of Type 1 diabetes. Diabetes 55(12), 3344-3350 (2006).
56. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus sermautomated hybrid control in pediatric patients with Type 1 diabetes using an artificial pancreas. Diabetes Care 31(5), 934-939 (2008).
57. Hovorka R, Chassin LJ, Wilinska ME et al. Closing the loop: the ADICOL experience. Diabetes Technol. Ther. 6(3), 307-318 (2004).
58. Galley P, Wagner R, Buck H et al. Use of subcutaneous continuous glucose measurements to drive real-time algorithm-directed insulin infusion recommendations. Diabetes Technol. Ther. 6, 245-246 (2004).
59. Hovorka R, Acerini CL, Allen J et al. Overnight sc-sc closed-loop control improves glucose control and reduces risk of hypoglycaemia in children and adolescents with Type 1 diabetes. Diabetes 57, A22 (2008).
60. Hovorka R, Acerini CL, Allen J et al. Good overnight closed-loop glucose control in children and adolescents with Type 1 diabetes following ingestion of large, rapidly and slowly absorbed evening meat. Diabetologia 51, 181 (2008).
61. Buckingham B, Cobry E, Clinton P et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol. Ther. 11(2), 93-97 (2009).
62. Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab. Res. Rev. 20(3), 178-188 (2004).
63. Zisser H. Quantifying the impact of a short-interval interruption of insulin-pump infusion sets on glycemic excursions. Diabetes Care 31(2), 238-239 (2008).
64. El-Khatib FH, Jiang J, Gerrity RG, Damiano ER. Pharmacodynamics and stability of subcutaneously infused glucagon in a Type 1 diabetic swine model in vivo. Diabetes Technol. Ther. 9(2), 135-144 (2007).
65. El-Khatib F, Jiang JX, Damiano E. Adaptive closed-loop control provides robust blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in ambulatory diabetic swine. Diabetes 56, A125 (2007).
66. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with Type 2 diabetes mellitus. Horm. Metab. Res. 34(9), 504-508 (2002).
67. Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW. The role of amylin and glucagon in the dampening of glycemic excursions in children with Type 1 diabetes. Diabetes 54(4), 1100-1107 (2005).
68. Kovatchev B, Raimondo D, Breton M, Patek S, Cobelli C. In silico testing and in vivo experiments with closed-loop control of blood glucose in diabetes. Presented at: 17th International Federation of Automatic Control (IFAC) World Congress. Seoul, South Korea, 6-11 July 2008.
69. Chassin LJ, Wilinska ME, Hovorka R. Evaluation of glucose controllers in virtual environment: methodology and sample application. Artif. Intell. Med. 32(3), 171-181 (2004).
70. Kovatchev B, Breton M, Dalla Man C, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of Type 1 diabetes. J. Diabetes Sci. Technol. 3(1), 43-55 (2009).
71. Man CD, Rizza RA, Cobelli C. Meal simulation model of the glucose-insulin system. IEEE Trans. Biomed. Eng. 54, 1740-1749 (2007).
72. Fabietti PG, Canonico V, Orsini-Federici M, Sarti E, Massi-Benedetti M. Clinical validation of a new control-oriented model of insulin and glucose dynamics in subjects with Type I diabetes. Diabetes Technol. Ther. 9(4), 327-338 (2007).
73. Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359(9324), 2140-2144 (2002).
74. Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in critically ill patients. N. Engl. J. Med. 345(19), 1359-1367 (2001).
75. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults - a meta-analysis. JAMA 300(8), 933-944 (2008).
76. Finfer S, Chittock DR, Su SY et al.; NICE-SUGAR study investigators. Intensive versus conventional glucose control in critically ill patients. N. Engl. J. Med. 360(13), 1283-1297 (2009).
77. Chee F, Fernando T, van Heerden PV. Closed-loop glucose control in critically ill patients using continuous glucose monitoring system (CGMS) in real time. IEEE Trans. Inf. Technol. Biomed. 7(1), 43-53 (2003).
78. Plank J, Blaha J, Cordingley J et al. Multicentric, randomized, controlled trial to evaluate blood glucose control by the model predictive control algorithm versus routine glucose management protocols in intensive care unit patients. Diabetes Care 29(2), 271-276 (2006).